BDSXHealthcare · Diagnostics & ResearchThe 7 Wall Street analysts covering Biodesix, Inc. hold a median 12-month price target of $40 — +87.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Biodesix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Value (17): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BDSX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +87.6% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $30 → $40 |
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $27 → $38 |
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $27 → $35 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $26 → $27 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 June 2026 | Roth Capital | Initiates | Buy | — |
| 25 June 2026 | Roth Capital | Initiates | Buy | $32 |
| 18 June 2026 | Canaccord Genuity | Maintains | Buy | $22 → $27 |
| 18 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 15 June 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Feb 2026 | William Blair | Upgrade | Outperform | — |
| 17 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 May 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 14 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 May 2025 | Lake Street | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BDSX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Biodesix, Inc. returned +180.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 49% of US stocks
Cheaper than 4% of US stocks
Cheaper than 89% of US stocks
Higher than 80% of US stocks
Higher than 69% of US stocks
Higher than 92% of US stocks
Higher than 21% of US stocks
Higher than 14% of US stocks
Higher than 3% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biodesix, Inc. has a market value of $222.1M and an enterprise value of $262.1M.
Revenue in the twelve months to 30 June 2026: $102.9M. The latest quarter grew 34.2% year on year.
Net income over the same four quarters: −$27.8M, a −27.0% net margin.
Diluted earnings per share, trailing twelve months: $−3.17.
Free cash flow in the twelve months to 30 June 2026: −$20.4M.
Trailing P/E: −4.5×; forward P/E: −95.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Biodesix, Inc. employs 334 people — $308K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biodesix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biodesix announced that members of its leadership team will present at two upcoming investor conferences.
Why it matters — BDSX watchers may note the scheduled investor presentations as an opportunity for the company to provide updates.
Biodesix (BDSX) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — BDSX watchers may note the improved Zacks rating and the optimism it reflects about the company’s earnings prospects.
Zacks Investment Research says Biodesix lacks the combination of two key ingredients it considers necessary for a likely earnings beat in the upcoming report. The headline asks whether the company will report negative earnings next week, while the excerpt provides no earnings estimate or result.
Why it matters — BDSX watchers may note the article’s cautious framing ahead of the company’s upcoming earnings report.
Biodesix announced it will report third-quarter 2026 financial results after market close on November 5, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the results and provide a general business update.
Why it matters — BDSX watchers can note the scheduled date and time for the company’s financial results and management update.
The American College of Chest Physicians published a new framework for lung nodule programs, developed by a multidisciplinary panel with experience across diverse clinical practices. The framework recommends biomarkers for risk stratification.
Why it matters — BDSX watchers may note the framework’s recommendation of biomarkers in lung nodule risk stratification.
The 7 Wall Street analysts covering Biodesix, Inc. have a median 12-month price target of $40, with estimates ranging from $35 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Biodesix, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biodesix, Inc. 76 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Biodesix, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +87.6% from the last close, and Ticker Nerd's factor model ranks Biodesix, Inc. 76 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biodesix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $41 over the next 12 months.
Biodesix, Inc. returned +180.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Biodesix, Inc. is a diagnostic solutions company focused on blood-based testing and development services for lung disease, with a strong emphasis on lung cancer care.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Biodesix to Participate in Upcoming Investor Conferences". Biodesix announced that members of its leadership team will present at two upcoming investor conferences.
Biodesix, Inc. is a diagnostic solutions company focused on blood-based testing and development services for lung disease, with a strong emphasis on lung cancer care. Biodesix provides commercial tests such as Nodify XL2 and Nodify CDT for lung nodule risk assessment, along with GeneStrat ddPCR, GeneStrat NGS, and VeriStrat to support diagnostic and treatment decisions in oncology. The company also serves biopharmaceutical, life sciences, and diagnostic partners with services that include biomarker discovery, assay design, clinical trial sample testing, regulatory support, reimbursement support, commercialization, and logistics. By combining laboratory diagnostics with research and development capabilities, Biodesix plays a specialized role in precision medicine and respiratory health, helping clinicians and industry customers address unmet needs in lung-related disease management.
CEO Mr. Scott Hutton · 334 employees · United States · https://www.biodesix.com
